The post-pandemic evolution of pharma-doctor digital interactions
M3’s Tim Russell and Maxim Polyakov, together with Digital Futureway’s Heather Hancock, discuss new research on how doctor engagement has been altered by COVID-19.
COVID-19 forced an unprecedented shift towards the virtual delivery of healthcare, suddenly compelling doctors increasingly to use digital means to care for their patients.
As healthcare resources and delivery were prioritised, there was also a massive and ongoing impact on growing waiting lists and time-lags for diagnosis and treatment.
That picture of how patient needs and patient-doctor interactions are changing will shortly be fully painted by the release of a new white paper from M3 on engaging doctors in a post-COVID-19 world.
The publication will also look at the pandemic’s impact on communications between the industry and doctors. Here, M3’s Tim Russell and Maxim Polyakov, together with pharma consultant Heather Hancock, discuss a key aspect of the new research: the evolving picture of pharma’s digital and face-to-face interactions with doctors.